Updated Results of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

被引：27

作者：

Jakubowiak, Andrzej J. ^{[1
]}

Anguille, Sebastien ^{[2
]}

Karlin, Lionel ^{[3
]}

Chari, Ajai ^{[4
]}

Schinke, Carolina ^{[5
]}

Rasche, Leo ^{[6
]}

San-Miguel, Jesus ^{[7
]}

Campagna, Michela ^{[8
]}

Hilder, Brandi W. ^{[9
]}

Masterson, Tara J. ^{[9
]}

Qin, Xiang ^{[9
]}

Renaud, Thomas ^{[10
]}

Tolbert, Jaszianne ^{[9
]}

Vishwamitra, Deeksha ^{[9
]}

Skerget, Sheri ^{[9
]}

Moreau, Philippe ^{[11
]}

机构：

[1] Univ Chicago, Chicago, IL USA

[2] Univ Antwerp, Univ Antwerp Hosp, Vaccine & Infect Dis Inst, Ctr Cell Therapy & Regenerat Med, Edegem, Belgium

[3] Ctr Hosp Lyon Sud, Pierre Benite, France

[4] Mt Sinai Sch Med, New York, NY USA

[5] Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR USA

[6] Univ Hosp Wurzburg, Wurzburg, Germany

[7] Univ Navarra, Pamplona, Spain

[8] Janssen Res & Dev, Madrid, Spain

[9] Janssen Res & Dev, Spring House, PA USA

[10] Janssen Res & Dev, Raritan, NJ USA

[11] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France

来源：

关键词：

D O I：

10.1182/blood-2023-187242

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4